CAS: 85650-56-2; Rel-Asenapine Maleate

上下游产品

CAS号65576-45-6 阿塞那平 | CAS号110-16-7 马来酸 | CAS号2444-36-2 2-氯苯乙酸 | CAS号57486-68-7 2-氯苯乙酸甲酯 | CAS号934996-79-9 5-氯-2-甲基-2,3-二氢... | CAS号2476-37-1 2,5-二氯苯乙酮 | CAS号108-95-2 苯酚 | CAS号1141493-78-8 (5-chloro-2-phe... | CAS号65576-45-6 阿塞那平 | CAS号128915-56-0 N-desmethylasenapine | CAS号128923-28-4 Org 5222 glucuronide

顺丁烯二酸 在 甲烷体系中,用 乙醇作为反应溶剂,反应 2.75H,获得 Asenapine Maleate
参考文献:Intermediate Compounds For The Preparation Of Trans-5-Chloro-2-Methyl-2,3,3A,12B-Tetrahydro-1H-Dibenz[2,3:6,7]Oxepino[4,5-C]Pyrrole
标题:Intermediate Compounds For The Preparation Of Trans-5-Chloro-2-Methyl-2,3,3A,12B-Tetrahydro-1H-Dibenz[2,3:6,7]Oxepino[4,5-C]Pyrrole

专利信息

专利号:US-2013274466-A1
优先权日:2010-09-27
标 题:Process for the preparation of tetracyclic derivatives and intermediate products used in the process
发明人：GORIN BORIS; DIXON CRAIG EDWARD; QU YANG
权利人:GORIN BORIS; DIXON CRAIG EDWARD; QU YANG; ALPHORA RES INC
摘要:A process for preparation of a compound of formula I or a pharmaceutically acceptable salt thereof, is disclosed. The process involves subjecting a compound of formula II to Ullmann-type conditions to effect an intra-molecular ring closure reaction to form the compound of formula I. The different substituents are as described in the specification. Further, the process can provide an alternate route for the synthesis of asenapine from starting materials that can be readily available.

专利号:US-9751877-B2
优先权日:2012-09-21
标题 :Substituted pyrido[1,2-a]pyrazines for the treatment of neurodegenerative and neurological disorders
发明人：PETTERSSON MARTIN YOUNGJIN; JOHNSON DOUGLAS SCOTT; SUBRAMANYAM CHAKRAPANI; O'DONNELL CHRISTOPHER JOHN; AM ENDE CHRISTOPHER WILLIAM; GREEN MICHAEL ERIC; PATEL NANDINI CHATURBHAI; STIFF CORY MICHAEL; TRAN TUAN PHONG; KAUFFMAN GREGORY WAYNE; STEPAN ANTONIA FRIEDERIKE; VERHOEST PATRICK ROBERT
权利人:PFIZER
摘要:Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I n nas defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

专利号:US-9505771-B2
优先权日:2011-05-18
标 题 :Stable micronised monoclin form of asenapine maleate and its synthesis
发明人：BERTRAN AGUSTI; TERRADAS JOSEP
权利人:BERTRAN AGUSTI; TERRADAS JOSEP; LABORATORIES LESVI S L
摘要:A stable micronized monoclinic form of asenapine maleate is described, which comprises 5% by weight or less of orthorhombic form or any other crystalline form of asenapine maleate, wherein the asenapine maleate has a particle size distribution characterized by a d90 equal to or below 40 μm. Processes for preparing the stable micronized monoclinic form of asenapine maleate are also described. Formula (I).

专利号:RU-2397164-C2
优先权日:2005-04-07
标题:INTERMEDIATE COMPOUNDS FOR SYNTHESIS OF TRANS-5-CHLORO-2-METHYL-2,3,3a,12b-TETRAHYDRO-1H-DIBENZ[2,3:6,7]-OXEPINO[4,5-c]PYRROLE

专利号:WO-2012172449-A1
优先权日:2011-06-13
标题:Lactams as beta secretase inhibitors
发明人：BRODNEY MICHAEL AARON
权利人:PFIZER; BRODNEY MICHAEL AARON
摘要:Compound and pharmaceutically acceptable salts of the compound are disclosed, wherein the compound has the structure (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed. The compound of formula I is useful as beta secretase inhibitor for use in the treatment of Alzheimer's and other neurodegenerative and/or neurological disorders.

专利号:US-2016229847-A1
优先权日:2013-10-04
标 题:Novel bicyclic pyridinones as gamma-secretase modulators
发明人：PETTERSSON MARTIN YOUNGJIN; AM ENDE CHRISTOPHER WILLIAM; GREEN MICHAEL ERIC; JOHNSON DOUGLAS SCOTT; KAUFFMAN GREGORY WAYNE; O'DONNELL CHRISTOPHER WILLIAM; PATEL NANDINI CHATURBHAI; STEPAN ANTONIA FRIEDERIKE; STIFF CORY MICHAEL; SUBRAMANYAM CHAKRAPANI; TRAN TUAN PHONG; VERHOEST PATRICK ROBERT
权利人:PFIZER
摘要:Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula II as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.